Brolucizumab for Wet Age-Related Macular Degeneration in Switch Patients: Long-Term Real-World Experience from a Tertiary Center
This study reports that brolucizumab provides favorable anatomical and functional outcomes and can reduce treatment burden in patients with nAMD due to its rapid and sustained efficacy and favorable safety profile.
Authors
- Claudia Fossataro (ORCID: https://orcid.org/0000-0001-9474-0517)
- Andrea Scupola (ORCID: https://orcid.org/0000-0003-4150-3504)
- Gustavo Savino (ORCID: https://orcid.org/0000-0002-9993-5986)
- Mattia Cusato
- Maria Grazia Sammarco
- Stanislao Rizzo (ORCID: https://orcid.org/0000-0001-6302-063X)
- Lorenzo Hu (ORCID: https://orcid.org/0009-0008-8349-5737)
- Marzia Michieletto
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Ophthalmologica
- Published
- 2025-09-17
- DOI
- https://doi.org/10.1159/000547471
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00